A Director at Inovio Pharmaceuticals is Exercising Options

By Carrie Williams

Today, a Director at Inovio Pharmaceuticals, Simon Benito, exercised options of Inovio Pharmaceuticals for $19.61K. The options were close to expired and Simon Benito disposed stocks.

This is Benito’s first transaction since reporting a Buy transaction on DRRX back in September 2017

The company has a one-year high of $9.86 and a one-year low of $3.76. Currently, Inovio Pharmaceuticals has an average volume of 868.6K.

Based on 3 analyst ratings, the analyst consensus is Strong Buy with an average price target of $11.67, reflecting a -56.6% downside.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Inovio Pharmaceuticals, Inc. engages in the development of active DNA immunotherapies for cancer and infectious diseases. Its portfolio of immune therapies includes SynCon immunotherapies and electroporation delivery systems. The company was founded on June 29, 1983 and is headquartered in Plymouth Meeting, PA.